Martin Shkreli and Jim Tananbaum were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Shkreli and Tananbaum were featured in the investment section, as LSIPR reports.
Name: Martin Shkreli
Organisation: Formerly of Turing Pharmaceuticals
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Martin Shkreli, Jim Tananbaum, Turing Pharmaceuticals, drugs, Foresite Capital, Jazz Pharmaceuticals,
